<3063> jGroup 684 +14
Rebound. After the closing of the 10th trading day, the financial results for the first quarter of the fiscal year ending in February 2025 were announced. The revenue was ¥2,717 million, a year-on-year increase of 5.6%, and the ordinary income was a profit of ¥75 million, which rebounded from the loss of ¥7 million in the same period of the previous year. The company was well-received for closing two directly-managed stores and continuing to improve personnel arrangement, productivity, and reduce headquarters expenses, as well as renovating and repairing existing stores and developing new businesses, which improved the revenue structure, achieving a significant performance improvement.
<4978> Reprocell 141 +3
Fluctuating. JTB announced that it will become the general agent of regenerative medical grade iPS exosomes and start selling them to medical institutions and clinics that use iPS exosomes through Japan Health Development Foundation. This caused a rapid rise in stock price but it is now fluctuating due to profit-taking selling. Exosomes are granular substances with a diameter of 50-150nm (nanometers) secreted from cells. Currently, exosomes secreted from adipose, umbilical cord, and dental pulp-derived stem cells are widely circulated for beauty purposes, and it is expected that the compound annual growth rate of the global market will be 30%.
<9245> Libero 1665 +67
Significant rebound. After the 10th day of trading, the company announced its preliminary monthly revenue and major KPI for June 2024 and is considered favorable news. Monthly sales for June continued to be strong, with sales of ¥0.329 billion, a year-on-year increase of 139.0%. In addition, the number of new lending units in June was 2,045, an increase of 124.3% compared to the same period last year.
<7049> Shikaku 561 +64
High for the year so far. After the 10th day of trading, the financial results for the first quarter of the 2025 February fiscal year were announced. Revenue was 1.33 billion yen, an 11.2% increase compared to the same period last year, and ordinary profit and loss surged to a black figure of 100 million yen, compared to a red figure of 1.047 billion yen in the same period last year, which is considered to be good news. As a result of raising the monthly basic fee for Shikaku Basic Services from 0.2 million yen to 0.3 million yen as of April 2024, although the number of Shikaku Basic Service contract companies has remained unchanged, sales have increased, and cost reduction efforts, with a focus on advertising and marketing expenses, have also met with success.
<9560> Progrid 1257 +195
Rapid rise. After the closing of the 10th trading day, the results for the third quarter of the fiscal year ending in August 2024 were announced. The revenue was ¥3,179 million, a year-on-year increase of 49.2%, and the operating profit was ¥444 million, a significant increase of 69.8%, which was well-received. In the fourth quarter, they plan to actively invest in marketing activities to expand their reach, but they expect to exceed their full-year performance forecast. The expansion of the market for individual and corporate English coaching is a tailwind. They also announced a change in dividend policy and will implement a year-end lump sum dividend of ¥13 (forecasted), which was previously non-existent.
<4890> Tsubota Laboratory 498 +24
Year-to-date high, temporarily hit the upper limit. On the 9th, they announced the results of specific clinical studies evaluating the safety and efficacy of TLG-005 (violet light glasses) for "Parkinson's disease" and "Depression", and on the 10th, they hit the upper limit, and it seems to still be seen as a material. No serious adverse events were observed in both studies, and results indicating efficacy were obtained. In response to these results, the company will continue to work on research and business development.